Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Data from the ETNA-AF-Europe Registry provide insights on edoxaban in clinical routine practice in subpopulations including frail patients and those with worsening renal function. ENVISAGE-TAVI
Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
May 15, 2021 12:00 ET | Source: Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Ann Arbor, Michigan, UNITED STATES
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p
Share:
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p
(0)
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA